Angiovist 282
Brand names,
Angiovist 282
Analogs
Angiovist 282
Brand Names Mixture
Angiovist 282
Chemical_Formula
C9H15N5O3
Angiovist 282
RX_link
No information avaliable
Angiovist 282
fda sheet
Angiovist 282
msds (material safety sheet)
Angiovist 282
Synthesis Reference
No information avaliable
Angiovist 282
Molecular Weight
241.247 g/mol
Angiovist 282
Melting Point
250-255 oC (hydrochloride salt)
Angiovist 282
H2O Solubility
>20 mg/mL (dichloride salt)
Angiovist 282
State
Solid
Angiovist 282
LogP
-1.783
Angiovist 282
Dosage Forms
No information avaliable
Angiovist 282
Indication
For the treatment of tetrahydrobiopterin (BH4) deficiency.
Angiovist 282
Pharmacology
Tetrahydrobiopterin (BH4) is used to convert several amino acids, including phenylalanine, to other essential molecules in the body including neurotransmitters. Tetrahydrobiopterin deficiency can be caused by mutations in GTP cyclohydrolase 1 (GCH1), 6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1), 6-pyruvoyltetrahydropterin synthase (PTS), and quinoid dihydropteridine reductase (QDPR) genes. These genes make the enzymes that are critical for producing and recycling tetrahydrobiopterin. If one of the enzymes fails to function correctly because of a gene mutation, little or no tetrahydrobiopterin is produced. As a result, phenylalanine from the diet builds up in the bloodstream and other tissues and can damage nerve cells in the brain. High levels of phenylalanine can result in signs and symptoms ranging from temporary low muscle tone to mental retardation, movement disorders, difficulty swallowing, seizures, behavioral problems, progressive problems with development, and an inability to control body temperature.
Angiovist 282
Absorption
No information avaliable
Angiovist 282
side effects and Toxicity
No information avaliable
Angiovist 282
Patient Information
No information avaliable
Angiovist 282
Organisms Affected
Humans and other mammals